Literature - Publication Review

Biopolymers Codelivering Engineered T Cells and STING Agonists can Eliminate Heterogenous Tumors

biopolymers-codelivering-engineering-t-cell-512x288

Adoptive cell transfer using chimeric antigen receptor (CAR-T) cell therapy in which the patient’s T-cells are extracted, genetically modified, and transferred back into the patient with the aim that these altered cells can recognize and attack cancer cells has revolutionized cancer immunotherapy. Although very successful in treating hematological malignancies, CAR T therapy is more challenging in treating solid tumors.

Learn how researchers at the Fred Hutchinson Cancer Research Center and University of Washington used the IVIS® Spectrum non-invasive imaging system to evaluate the synergistic antitumor effect of co-delivery of CAR T cells and STING-agonists via biopolymer scaffolds in an orthotopic murine model of pancreatic cancer.

For research use only. Not for use in diagnostic procedures. 

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Biopolymers Codelivering Engineered T Cells and STING Agonists can Eliminate Heterogenous Tumors

Download Literature - Publication Review